GT
TRAX

Glenmede Trust’s First Tracks Biotherapeutics TRAX Stock Holding History

Glenmede Trust’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Buy
+12,240
New +$229K ﹤0.01% 1256

Other funds holding TRAX

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Glenmede Trust's TRAX Position: Q2 2026 in Review

Glenmede Trust opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 12,240 shares worth $246K. The stake represents ﹤0.01% of the portfolio and ranks #1256 among its holdings.

150 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Glenmede Trust held 12,240 shares of First Tracks Biotherapeutics worth $246K as of Q2 2026.
  • First Tracks Biotherapeutics was a new Glenmede Trust position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1256 holding.
  • 150 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.